Sign in
Taking peopleNo phase

Biodegradable Stents in Primary Sclerosing Cholangitis

Key facts

Who runs it
King's College Hospital NHS Trust
Where
United Kingdom1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
20 people, planned
Started
1 Mar 2026
Expected to end
1 Apr 2027
Type of study
Interventional
Treatments tested
  • archimedes stent
Record updated
29 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • PSC patients with a high grade stricture

Who cannot take part

  • Prior stenting or balloon dilatation within the previous 4 months
  • Change of UDCA therapy within 4 weeks
  • Suspicion of cholangiocarcinoma, reflected by an imaging study suggestive of metastasis, MRCP with mass lesion with contrast enhancenment, or rise in CA19.9 of > 63 U/ml in the previous 4 months together with an absolute value > 130 U/ml
  • HIV or acute or chronic hepatitis B or hepatitis C or substance (drug or alcohol) misure within the previous 2 years
  • Signs of current malignancy other than basal cell carcinoma
  • Estimated transplant free survival < 2 years as calculated by Mayo score > 2
  • Signs of bacterial cholangitis as defined by definite cholangitis
  • Inability to give informed consent
  • Biliary cirrhosis with Child Pugh score > 8
  • Life expectancy < 24 months
  • Women pregnant at the time of screening

This trial is currently available in United Kingdom.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

In patients with PSC, endoscopic therapy of strictures aims to improve cholestasis by relieving the biliary obstruction via endoscopic biliary dilatation with consideration of plastic stents in strictures refractory to dilatation due to the risk of pancreatitis and cholangitis . Short term stents have been shown to have similar recurrence-free rates compared to dilatation in a randomised control trial; however, this was terminated after interim analysis due to higher rates of serious adverse events in the stent group. The long term benefits are unclear; however, it may lead to improved survival compared to predicted survival. In this group of patients with limited treatment options, biodegradable stents may provide an attractive additional treatment modality in the management of high grade strictures.

The group in the trial

  • Archimedes stent insertionTreatment being tested

    Archimedes stent insertion at ERCP for patients with PSC and a HGS

    Treatment: archimedes stent

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pilot Study of Biodegradable STents in Primary Sclerosing Cholangitis - BSTPSC
Record updated
29 May 2026